

UTILITY **PATENT APPLICATION TRANSMITTAL** 

Attorney Docket No. 16517.257 First Inventor Sherri M. BROWN, et al.

Nucleic Acid Molecules and Other Molecules Associated with the Title Gibberellin Pathway

(Only for new nonprovisional applications under 37 C.F.R. 1.53(b))

Express Mail Label No.

4	APPLICATION EL	EMENTS			A = = = = = =	40		
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.		ADDI	ASSISTANT Commissioner for Patents Box Patent Application Washington, DC 20231					
1.	Fee Transmittal Form (e.g., PTO/SB/17)			7. CD-ROM or CD-R in duplicate, large table or				
2. 🗀	(Submit an original and a duplicate for fee processing)			Computer Program (Appendix)				
2. Applicant claims small entity status.  See 37 CFR 1.27.			8. Nuc	8. Nucleotide and/or Amino Acid Sequence Submission				
3. 🛛				(if applicable, all necessary) a. ⊠ Computer Readable Form (CRF)				
(preferred arrangement set forth below)			b. Sr	b. Specification Sequence Listing on:				
Descriptive title of the Invention     Cross References to Related Applications			i. [	i. CD-ROM or CD-R (2 copies); or				
Statement Regarding Fed sponsored R & D     Reference to sequence listing, a table,     or a computer program listing appendix			ii.	ii. 🛛 paper				
			C. 🔀	c. X Statements verifying identity of above copies				
	- Background of the Invention			ACCOMPANYING APPLICATIONS PARTS				
- Brief Summary of the Invention			9. 🗌	9. Assignment Papers (cover sheet & document(s))				
ł	Brief Description of the Drawings ( if filed)     Detailed Description			37 C.F.R.	§3.73(b) State	ement   Power of		
	- Claim(s)			(when there is an assignee) Attorney				
	- Abstract of the Disclosure		11. 🗌	English Tı	ranslation Do	cument (if applicable)		
		otal Sheets ] otal Pages 15 1	12. 🗌		n Disclosure	Copies of IDS Citations		
a. Newly executed (original or copy)			13. 🖂					
Ь. □	Copy from a prior application (		14. 🖾			d (MPEP 503)		
_	(for a continuation/divisional with Box 18 completed)			(Should be specifically itemized)				
i. [	DELETION OF INVENTOR		15. 🗌	15. Certified Copy of Priority Document(s)  (if foreign priority is claimed)				
_	Signed statement attached deleting	ninventor(s)	16 🖂					
ľ	named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).			16.  ☐ Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35				
6. □ Ap				or its equiv	valent.	idst ditacit form F 10/3B/33		
7 ppiloditor bata Steet. See 37 CFK 1.76			17. 🗌	Other:	-			
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment,								
Or in an App	or in an Application Data Sneet under 37 CFR 1.76:							
⊠ Cont	" " The second	Continuation-in-par	t (CIP)	CIP) of prior application No: 09 / 252,974				
	Prior application information: Examiner ZEMAN, M.				Group / Art Unit: 1631			
For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying or divisional application and is hereby incorporated by reference.								
The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.								
17. CORRESPONDENCE ADDRESS								
Custon	ner Number or Bar Code Label	283	81		or 🗆 C	Correspondence address below		
(Insert Customer No. or Attach bar code label here)						en depondence address below		
Name	David R. Marsh							
	June E. Cohan							
Address	ARNOLD & PORTER							
555 12th Street, N.W.								
City	Washington	State	D.C.		Zip Code	20004-1206		
Country	USA	Telephone	202-942-50	000	Fax	202-942-5999		
Name (Print/Type) David R. Marsh / June E. Cohan Re			Registration	egistration No. (Attorney/Agent) 41,408 / 43,741				
Signature	Signature				Date	Sept. 19,2001		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 2021. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application. Washington, DC 20231.



## ARNOLD & PORTER

202.942.5000 202.942.5999 Fax

555 Twelfth Street, NW Washington, DC 20004-1206



September 19, 2001

ommissioner for Patents Washington, D.C. 20231

**Box Patent Application** 

Re:

U.S. Continuation Application

Appl. No.:

To Be Assigned

Filed:

Herewith

For:

Nucleic Acid Molecules and Other Molecules

Associated with the Gibberellin Pathway

Inventors:

Sherri M. BROWN, et al.

Atty. Docket: 16517.257

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office.

- Utility Patent Application Transmittal (PTO/SB/05); 1.
- 2. U.S. Non-Provisional Application entitled:

Nucleic Acid Molecules and Other Molecules Associated with the Gibberellin **Pathway** 

and naming as inventors:

Sherri M. Brown, Gregory R. Heck and Jingdong Liu;

the application consisting of:

- A specification containing: a.
  - 214 pages of a description prior to the claims; (i)
  - 4 pages of claims (9 claims); and (ii)
  - a one (1) page abstract; (iii)
- a Statement Regarding Sequence Submission; 3.

London

Northern Virginia

## ARNOLD & PORTER

Continuation Application Atty. Dkt. 16517.257

Page 2

- 4. the sequence listing in computer readable form (i.e., CRF) (1 diskette);
- 5. a paper copy of the sequence listing (34 pages);
- 6. a Request and Certification Under 35 U.S.C. 122(b)(2)(B)(i) (PTO/SB/35);
- 7. Preliminary Amendment;
- 8. check No. 139309 in the amount of \$710 to cover the basic continuation filing fee; and
- 9. two (2) return postcards.

Submitted herewith is a sequence listing and a sequence listing in Computer Readable Form (CRF) on diskette, in compliance with 37 C.F.R. §§ 1.52(e), 1.77, and 1.823.

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and unofficial application number and returned as soon as possible.

This application is a continuation of prior application no. 09/252,974 filed on February 19, 1999.

Applicants do not believe that any fees other than the basic filing fee (\$710) are due in conjunction with this filing. However, should any additional fees be required, the Patent and Trademark Office is authorized to charge any additional fees or credit any overpayment to Arnold and Porter deposit account 50-1824 referencing matter number 16517.257. This letter is submitted in duplicate.

Respectfully submitted.

David R. Marsh (Reg. No. 41,408) June E. Cohan (Reg. No. 43,741)

**Enclosures** 

PTO/SB/35 (11-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST AND CERTIFICATION		lamed Inventor	Sherri M. BROWN, et al.	
UNDER 35 U.S.C. 122(b)(2)(B)(i)	Title	Nucleic Acid Molecules and Other Molecules Associated with the Gibberellin Pathway		
	Atty Docket Number		16517.257	

I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).

September 19,2001

David R. Marsh ( Reg. No 41,408) June E. Cohan (Reg. No. 43,741)

Typed or printed name

Signature

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. **Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).** 

Burden Hour Statement: This collection of information is required by 37 CFR 1.213(a). The information is used by the public to request that an application not be published under 35 U.S.C. 122(b) (and the PTO to process that request). Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 6 minutes to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

|--|

## U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FEE RECORD SHEET

01/20/2001 STEUWEL1 00000056 09955216

01 FCs101

710.00 OP